Initial phase 1 Parkinson's gene therapy results were similar to placebo in other Parkinson's surgeries.
Sanofi reviewed the Parkinson's gene therapy clinical data and walked away.
Voyager needs to raises money; it will most likely be an equity offering before phase 1b and phase 1 posterior trajectory data is released.